Niopeg (pegfilgrastim)

pCPA File Number: 23033
Negotiation Status:
Active Negotiation
Indication(s):
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drug.
Sponsor/Manufacturer:
Nora Pharma Inc.
CDA-AMC Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable